Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock. The award covers 200,000 stock options with an exercise price of $0.29 per share and an expiration date of April 8, 2036.
These options vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Sandercock holds 200,000 stock options directly, reflecting a routine compensation-related equity award rather than an open-market transaction.
Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Warren holds 250,000 stock options directly.
Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Baker holds 100,000 stock options directly.
Cue Biopharma, Inc. reports that partner Boehringer Ingelheim has selected its first compound for lead optimization under their April 2025 collaboration focused on differentiated B cell depletion molecules, including Cue’s CUE-501 candidate. This preclinical milestone triggers a $7.5 million payment to Cue Biopharma, which is expected in May 2026.
The company notes that, despite this milestone, it continues to face risks typical for an early-stage biotech, including limited operating history, limited cash, a history of losses, and a current going concern determination about its ability to fund operations beyond the next twelve months.
Cue Biopharma announced a leadership change, appointing Chief Financial and Business Officer Lucinda Warren as Interim President and Chief Executive Officer effective March 27, 2026. She will also retain her finance and business responsibilities and receives a base salary of $525,000 plus a $10,000 monthly interim supplement.
Warren is eligible for an annual bonus up to 45% of base salary and a future stock option equal to about 1.0% of outstanding shares upon achieving a financing milestone. Former CEO Usman Azam resigned on March 26, 2026 and will receive cash severance of $232,500 and up to 12 months of COBRA premium payments under a separation agreement.
Cue Biopharma, Inc. has filed an S-3 registration statement to register up to $300,000,000 of securities, covering debt, common and preferred stock, subscription rights, units and warrants. The filing also includes an at-the-market sales agreement with Jefferies to sell up to $12,666,282 of common stock from time to time.
The prospectus states the ATM agent fee is 3.0% of gross proceeds and cites a public float of $37,998,848 based on March 13, 2026 and 97,283,278 shares held by non-affiliates. The prospectus emphasizes that specific terms for any offering will be set forth in prospectus supplements and warns of the risks described under "Risk Factors."
Cue Biopharma, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 13, 2026. The agenda includes electing seven directors for one-year terms, ratifying RSM US LLP as auditor, and an advisory vote on executive compensation.
A key proposal seeks approval to amend the certificate of incorporation to allow a reverse stock split of common shares at a ratio between 1-for-30 and 1-for-50, with exact timing and ratio left to the board’s discretion. The record date is March 9, 2026, when 97,660,791 common shares were outstanding.
Cue Biopharma reported significantly higher collaboration revenue for 2025, driven by a new strategic collaboration and license agreement with ImmunoScape. Collaboration revenue rose to $21.9 million in the fourth quarter from $1.6 million a year earlier and to $27.5 million for the full year from $9.3 million in 2024, leading to fourth quarter net income of $1.6 million and a reduced full-year net loss of $26.6 million compared with $40.7 million in 2024.
The ImmunoScape agreement provides total upfront payments of $15 million, of which Cue received $9.5 million (net of withholding taxes) in the fourth quarter of 2025 and is entitled to an additional $5 million in November 2026, plus a 40% equity stake and eligibility for high-single digit royalties. The company advanced its lead autoimmune candidate CUE-401 toward IND readiness, reporting preclinical toxicology and pharmacology data in which CUE-401 was well tolerated with no adverse events observed and presenting supportive in vivo and in vitro data at a major immune regulation meeting. As of December 31, 2025, Cue Biopharma had $27.1 million in cash and cash equivalents, while continuing to operate at a full-year loss.